Metcalfe Su M
University of Cambridge, Biomedical Campus, Cambridge, UK.
LIFNano Therapeutics, Cambridge, UK.
Med Drug Discov. 2020 Mar;5:100019. doi: 10.1016/j.medidd.2020.100019. Epub 2020 Mar 19.
Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. Governments will not be able to minimise both deaths from COVID-19 and the economic impact of viral spread in mitigation of this current COVID-19 pandemic, according to Anderson et al. 2020 [1], Keeping mortality as low as possible will be the highest priority for individuals; hence governments must put in place measures to ameliorate the inevitable economic downturn. The current global picture shows small chains of transmission in many countries and large chains resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan. Most countries are likely to have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short time frame.
人冠状病毒hCoV-19具有高致病性，会引发严重肺炎并伴有病毒快速复制。2019年12月在中国武汉出现后，当前的COVID-19疫情迅速蔓延，人际传播不断扩大，现已演变成一场全球卫生突发事件，达到了大流行的规模。根据安德森等人2020年的研究[1]，在缓解当前这场COVID-19大流行时，各国政府无法同时将COVID-19导致的死亡人数和病毒传播造成的经济影响降至最低。尽可能降低死亡率将是个人的首要任务；因此，各国政府必须采取措施缓解不可避免的经济衰退。目前全球的情况是，许多国家存在小规模传播链，而在少数国家，如意大利、伊朗、韩国和日本，则出现了导致广泛传播的大规模传播链。在任何缓解措施产生影响之前，大多数国家可能至少在早期阶段就已经出现了COVID-19传播。问题的规模极其巨大。在此，我探讨利用干细胞提高患者对COVID-19的生物抵抗力的新方法，以及如何利用合成干细胞扩大益处并简化流程，以便在短时间内满足后勤需求。
